{"id":1001703,"date":"2026-09-09T07:03:01","date_gmt":"2026-09-09T11:03:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/"},"modified":"2026-09-09T07:03:01","modified_gmt":"2026-09-09T11:03:01","slug":"schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/","title":{"rendered":"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs"},"content":{"rendered":"

<\/p>\n

Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics<\/b>, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs<\/b><\/p>\n

Tectora secures $55 million Series A investment from NEA and RA Capital Management<\/i><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–
\nSchr\u00f6dinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital.<\/p>\n

\nIn connection with the transaction, Schr\u00f6dinger contributed two early-stage small molecule programs (SDGR-4594 and SDGR-8139) and, in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora will partner with Schr\u00f6dinger\u2019s drug discovery experts and leverage Schr\u00f6dinger\u2019s computational platform at scale to further advance these programs to clinical candidates.<\/p>\n

\n\u201cSchr\u00f6dinger has a track record of creating and enabling programs for licensing to pharma companies or joining forces with venture funds to build successful biotechnology companies such as Nimbus, Morphic, Structure and Ajax. These partnerships have collectively generated over $750 million in proceeds to Schr\u00f6dinger,\u201d said Karen Akinsanya, Ph.D., President, Therapeutics R&D, and Chief Strategy Officer, Partnerships, at Schr\u00f6dinger. \u201cWe co-founded Tectora with NEA and RA Capital to pair our breakthrough science with the dedicated capital and industry expertise needed to rapidly advance these programs to patients.\u201d<\/p>\n

\n\u201cAs early-stage company builders we look for opportunities where exceptional science is paired with a motivated entrepreneurial team,\u201d said J.C. Lopez, Principal, New Enterprise Associates. \u201cWe believe the Tectora team, paired with Schr\u00f6dinger\u2019s internal drug discovery team and industry-leading computational platform, will be able to successfully advance programs against historically challenging immunology and inflammation targets.\u201d<\/p>\n

\n\u201cWe were drawn to the opportunity to leverage Schr\u00f6dinger\u2019s drug discovery expertise and capabilities to develop therapeutics against high-value, validated targets,\u201d said Jenna Hebert, Ph.D., Investment Director, RA Capital Management. \u201cImmunology and inflammation remain areas of immense unmet patient need, and we are excited to co-found Tectora to advance these high-potential programs through preclinical development and into the clinic.\u201d<\/p>\n

About Tectora Therapeutics
\n
<\/b>Tectora Therapeutics is a privately held biotechnology company developing differentiated oral medicines for immune mediated diseases. The company is focused on translating clinically validated biology into convenient oral medicines for patients. By partnering with Schr\u00f6dinger, Tectora leverages advanced computational tools, drug discovery expertise, and preclinical capabilities to advance its initial programs. Tectora aims to build a broad pipeline of medicines for patients with significant unmet need. For more information, please visit https:\/\/tectoratx.com\/<\/a>.<\/p>\n

About Schr\u00f6dinger
\n
<\/b>Schr\u00f6dinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schr\u00f6dinger\u2019s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schr\u00f6dinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. To learn more, visit www.schrodinger.com<\/a>, follow us on LinkedIn<\/a>, or visit our blog, Extrapolations.com<\/a>.<\/p>\n

About New Enterprise Associates
\n
<\/b>New Enterprise Associates, Inc. (NEA)<\/i><\/a> is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has more than $35 billion in assets under management as of December 31, 2025, and invests in technology and healthcare companies at all stages in a company\u2019s lifecycle, from seed stage through IPO. The firm’s long track record of investing includes more than 285 portfolio company public listings and more than 510 mergers and acquisitions. For more information, please visitwww.nea.com<\/i><\/a>.<\/i><\/p>\n

About RA Capital Management
\n
<\/b>Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital\u2019s knowledge engine is guided by TechAtlas, its science-first internal research division. Raven, RA Capital\u2019s healthcare incubator, offers entrepreneurs and innovators a comprehensive business-building platform for biomedical innovation. RA Capital has over 250 employees and $16 billion in assets under management as of June 30, 2026. Learn more at www.racap.com<\/a>.<\/p>\n

Cautionary Note Regarding Forward-Looking Statements
\n
<\/b>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding our ability to realize potential milestone and royalty payments, the risk that we may not realize the expected benefits of the collaboration with Tectora, the initiation, timing, progress and results of Tectora\u2019s initial programs, and the potential advantages of Schr\u00f6dinger\u2019s computational platform. Statements including words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schr\u00f6dinger\u2019s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schr\u00f6dinger\u2019s control, including the expected benefits of, and opportunities related to, the collaboration with Tectora, Tectora\u2019s ability to obtain sufficient funding and advance its initial programs, the uncertainties inherent in drug development and commercialization, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals, its ability to further develop its computational platform, its reliance on third-party collaborators, and the ability of Schr\u00f6dinger and Tectora to retain and hire key personnel, and other risks detailed under the caption \u201cRisk Factors\u201d and elsewhere in the company\u2019s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 5, 2026, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schr\u00f6dinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260909340138\/en\/<\/a><\/span><\/p>\n

Jaren Madden (Investors and Media)
\n<\/b>
Schr\u00f6dinger, Inc.
\n<\/b>
jaren.madden@schrodinger.com
\n<\/a>
617-286-6264<\/p>\n

Matthew Luchini (Investors)
\n<\/b>
Schr\u00f6dinger, Inc.
\n<\/b>
matthew.luchini@schrodinger.com
\n<\/a>
917-719-0636<\/p>\n

Theresa Masnik (Media)
\n<\/b>
SHIFT Communications
\n
schrodingerpr@shiftcomm.com
\n<\/a>
212-229-1037<\/p>\n

KEYWORDS:<\/b> New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Technology Research Clinical Trials Health Technology Software Biotechnology Health Pharmaceutical Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs Tectora secures $55 million Series A investment from NEA and RA Capital Management NEW YORK–(BUSINESS WIRE)– Schr\u00f6dinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital. In connection with the transaction, Schr\u00f6dinger contributed two early-stage small molecule programs (SDGR-4594 and SDGR-8139) and, in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora … <\/p>\n

Continue reading “Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1001703","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSchr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs Tectora secures $55 million Series A investment from NEA and RA Capital Management NEW YORK–(BUSINESS WIRE)– Schr\u00f6dinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital. In connection with the transaction, Schr\u00f6dinger contributed two early-stage small molecule programs (SDGR-4594 and SDGR-8139) and, in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora … Continue reading "Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-09T11:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs\",\"datePublished\":\"2026-09-09T11:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/\"},\"wordCount\":1175,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/\",\"name\":\"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-09-09T11:03:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/","og_locale":"en_US","og_type":"article","og_title":"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - Market Newsdesk","og_description":"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs Tectora secures $55 million Series A investment from NEA and RA Capital Management NEW YORK–(BUSINESS WIRE)– Schr\u00f6dinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital. In connection with the transaction, Schr\u00f6dinger contributed two early-stage small molecule programs (SDGR-4594 and SDGR-8139) and, in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora … Continue reading \"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-09T11:03:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs","datePublished":"2026-09-09T11:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/"},"wordCount":1175,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/","name":"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-09-09T11:03:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260909340138r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/schrodinger-announces-licensing-and-collaboration-agreement-with-tectora-therapeutics-a-new-biotechnology-company-it-co-founded-to-advance-immunology-and-inflammation-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Schr\u00f6dinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1001703"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001703\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1001703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1001703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1001703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}